Talk:Semaglutide

2025 FDA kidney risk-reduction indication

I want to propose a short addition in Medical uses to reflect the Jan 28, 2025 U.S. FDA approval of a semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with T2D and CKD.

There are also recent systematic reviews/meta-analyses and guidelines supporting kidney-outcome benefits with GLP-1 RAs, with FLOW providing trial evidence, e.g, in Lancet Evathedutch (talk) 16:27, 19 September 2025 (UTC)

The page is currently unprotected and that addition doesn't look controversial, so just go ahead and add it using the Lancet source. Worst case scenario, someone objects and we come back here to discuss. QuicoleJR (talk) 17:54, 19 September 2025 (UTC)

Proposed addition to Medical uses section (COI edit request)

Hello, I have a conflict of interest as an employee of Truveta and therefore will not edit the article directly. I am requesting an independent editor’s review.

I propose adding a brief summary of a 2025 peer-reviewed cohort study examining real-world discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among U.S. adults with overweight or obesity. The study does not evaluate Truveta itself; it uses electronic health record data from multiple U.S. health systems that contribute data to Truveta. The findings provide updated evidence relevant to long-term treatment patterns described in the Medical uses section, particularly for semaglutide used for weight management.

Proposed sentence:

A 2025 cohort study of adults with overweight or obesity treated with dual-labeled GLP-1 receptor agonists, including semaglutide, found that many patients discontinued therapy and later restarted it, reporting substantial variability in real-world treatment persistence and medication cycling.

I suggest placing this sentence in the "Medical uses" section, in the paragraph describing Wegovy for long-term weight management, immediately after the existing sentence noting that many individuals regain weight after discontinuing semaglutide.

Thank you for your consideration.

Lyolek25 (talk) 21:53, 11 December 2025 (UTC)

As this remains preliminary research, it doesn't qualify as an encyclopedic source. We should wait for a secondary WP:MEDRS review or clinical guideline. Cohort studies are insufficient in evidence quality according to WP:MEDASSESS, left pyramid. Zefr (talk) 22:12, 11 December 2025 (UTC)

Avoiding coverage of generic and compounded versions

In and previously , @Whywhenwhohow removed sourced information about the generic versions of this drug, and worldwide coverage of their development and approval. I request an explanation for these edits, since the edit summaries stated what was done, but not why.

The proliferation of alternatives to the Novo Nordisk drugs is the most important recent development, and is essential to coverage of semaglutide.

• The coverage of the different kinds of generics, and worldwide approaches matters. Without it, the reader is not advised that many companies believe it is possible (legally, economically and technically) to replicate the drug, and that these efforts are underway (the process is furthest in Canada, followed closely by India, Brazil, China, etc.).
• Cost is the subject of immense controversy, and therefore the industry attitude to compounds and different access to price-sensitive consumers matters, as does the price elasticity.

TheFeds 00:05, 26 January 2026 (UTC)

The removed text was news and predictions. Please see WP:CRYSTAL, WP:NOTNEWS, and WP:MEDMOS. --Whywhenwhohow (talk) 22:47, 26 January 2026 (UTC)

Please be specific about which items you object to.

Regarding WP:CRYSTAL, that policy is principally concerned about entire articles (a notability standard). In any event, these facts are collectively well-cited, and pertain to intermediate steps in an ongoing chain of events whose steps follow logically from one another. The sources are not guessing, and we're not guessing by citing the sources.

Regarding WP:NOTNEWS, that policy isn't especially relevant. We're not giving first-hand reports, routine announcements or people-focused gossip.

There are many aspects to WP:MEDMOS, so you'll need to be precise. But note also that this is not just a medical article. Economic supply and demand, and comparative national pharmaceutical policy are important, and not squarely addressed in that medicine-focused guideline. TheFeds 23:16, 26 January 2026 (UTC)

After waiting a reasonable period for further information, I restored the material at issue. If there is a proposal to be selective about companies or countries to include, or a desire to disfavour sources, please state it here. TheFeds 08:02, 31 January 2026 (UTC)

Mechanism of action, Side effects

First, wrong order of the paragraphs.

Second, as to the knowledge, total ignorance and incompetence of the editors who contributed to these paragraphs.

The Mechanism of action shall be replaced by a meaningful and basic description of the human body metabolism. Then which way a synthetic GLP-1 intake (ozempic, for example) takes over the role of the natural GLP-1 and destroys normal functions of the metabolism.

Then, in the Side effects must be explained body weight loss as proportion of muscle mass loss(40-50%) and fat tissue loss (50-60%). After stopping taking the "medicine" fat tissue gets its previous values quickly and muscle loss slowly and incompletely. This causes accelerated aging of human body, stomach perase that might become cronic and lot more.

A qualified editor must have the highest academic credentials in medicine, deep understanding the human body metabolicsm. role of the autonomous neural system, brain, liver, pancreas, gastro intestines in it. ~2026-17554-22 (talk) 15:44, 23 March 2026 (UTC)

If you believe the article contains inaccuracies...then please provide high-quality secondary medical sources supporting the proposed changes. Some of the your statements, such as GLP-1 receptor agonists "destroying" normal metabolism or causing accelerated aging, would require strong evidence from reliable medical literature before they could be included in the article. Chronos.Zx (talk) 01:48, 31 May 2026 (UTC)

Anhedonia

Should we mention the fact that one side effect that has been noted is anhedonia? Source: https://www.washingtonpost.com/health/2026/04/16/ozempic-personality-glp1-side-effects/ ~2026-20625-89 (talk) 01:23, 20 May 2026 (UTC)

Could you contextualize, in light of a possible opposite effect suggested at Anhedonia#Glucagon-like_peptide_1_receptor_agonists_(GLP-1RAs)? TheFeds 05:45, 20 May 2026 (UTC)

Etymology

Suggestion for text in the wiki-article? (Such as: "Semaglutide" is (or is not) a portmanteau.)

Source for etymology? ~2026-32164-41 (talk) 01:48, 3 June 2026 (UTC) ~2026-32164-41 (talk) 01:52, 3 June 2026 (UTC)